Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zhengye Biotechnology Holding FCF Margin %?
Zhengye Biotechnology HoldingZYBT -3.08%20 FCF Margin % is 28.38% as of Dec. 2025, which is 1022% above its 10-year median of 2.53. GuruFocus rates ZYBT with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 959 Drug Manufacturers companies, Zhengye Biotechnology Holding ranks worse than 54.74% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhengye Biotechnology Holding FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Zhengye Biotechnology Holding's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhengye Biotechnology Holding (ZYBT) has a FCF Margin % of 28.38% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhengye Biotechnology Holding and its competitors. This is 1022% above median its historical median of 2.53. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #525 out of 959 companies in the Drug Manufacturers industry, placing it in the top 54.7%.
Is Zhengye Biotechnology Holding's FCF Margin % too high?
Zhengye Biotechnology Holding's current FCF Margin % of 28.38% is 1022% above median its 10-year median of 2.53. The Drug Manufacturers industry median FCF Margin % is 2.51. Zhengye Biotechnology Holding's value of 28.38% is 1030.7% above this industry median. Based on the distribution chart, Zhengye Biotechnology Holding ranks #525 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's FCF Margin % compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #525 out of 959 companies for FCF Margin %. This places Zhengye Biotechnology Holding in the lower half of its industry. The industry median FCF Margin % is 2.51. Zhengye Biotechnology Holding's value of 28.38% is 1030.7% above this benchmark. While the company's 10-year median is 2.53 vs. the industry median of 2.51, Zhengye Biotechnology Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhengye Biotechnology Holding's current FCF Margin % of 28.38% is 1030.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhengye Biotechnology Holding and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhengye Biotechnology Holding's current FCF Margin % is 28.38%, which is 1022% above median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current FCF Margin % of 28.38%. The current FCF Margin % is 28.38%, which is 1022% above median its 10-year median of 2.53 and 1030.7% above the Drug Manufacturers industry median of 2.51. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current FCF Margin % is 28.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score
Get the complete analysis for ZYBT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYBT has been successfully added to your 
